Positron emission tomography scanning for the diagnosis and management of lung cancer

Current Treatment Options in Oncology

Volumn 5, Issue 1, 2004, Pages 63-73

  Line, Bruce R ^a   White, Charles S ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; METHODOLOGY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASTIC PROCESSES; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 1542756158     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0007-5     Document Type: Review

References (42)

1. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM: Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975, 16:210-224.
2. Lardinois D, Weder W, Hany TF, et al.: Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507.
3. Shreve PD, Steventon RS, Deters EC, et al.: Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998, 207:431-437.
4. Delbeke D, Videlefsky S, Patton JA, et al.: Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med 1995, 36:2110-2119.
5. Lillington GA, Caskey CI: Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 1993, 14:111-119.
6. Good CA, Wilson TW: The solitary circumscribed pulmonary nodule: study of seven hundred five cases encountered roentgenologically in a period of three and one-half years. J Am Med Assoc 1958, 166:210-215.
7. Dewan NA, Shehan CJ, Reeb SD, et al.: Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997, 112:416-422.
8. Gould MK, Maclean CC, Kuschner WG, et al.: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924.
9. Lowe VJ, Hoffman JM, Delong DM, et al.: Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994, 35:1771-1776.
10. Dewan NA, Gupta NC, Redepenning LS, et al.: Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993, 104:997-1002.
11. Gupta NC, Frank AR, Dewan NA, et al.: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992, 184:441-444.
12. Higashi K, Ueda Y, Seki H, et al.: Fluorine-18-FDG-PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998, 39:1016-1020.
13. Erasmus JJ, McAdams HP, Patz EF Jr, et al.: Evaluation of primary pulmonary carcinoid tumors using FDG-PET. AJR Am J Roentgenol 1998, 170:1369-1373.
14. Patz EF Jr, Lowe VJ, Hoffman JM, et al.: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993, 188:487-490.
15. Langen KJ, Braun U, Rota KE, et al.: The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993, 34:355-359.
16. McKenna RJ Jr, Libshitz HI, Mountain CE, McMurtrey MJ: Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest 1985, 88:206-210.
17. Arita T, Kuramitsu T, Kawamura M, et al.: Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995, 50:1267-1269.
18. Arita T, Matsumoto T, Kuramitsu T, et al.: Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 1996, 110:1004-1008.
19. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL: Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta-analytic comparison of PET and CT. Radiology 1999, 213:530-536.
20. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr: Non-small cell lung cancer: FDG-PET for nodal staging in patients with stage I disease. Radiology 2000, 215:886-890.
21. Bury T, Dowlati A, Paulus P, et al.: Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997, 10:2529-2534.
22. Kalff V, Hicks RJ, MacManus MP, et al.: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111-118.
23. Mah K, Caldwell CB, Ung YC, et al.: The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002, 52:339-350.
24. Seltzer MA, Yap CS, Silverman DH, et al.: The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002, 43:752-756.
25. Kalff V, Hicks RJ, MacManus MP, et al.: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111-118.
26. Coleman RE: PET in lung cancer. J Nucl Med 1999, 40:814-820.
27. Eschmann SM, Friedel G, Paulsen F, et al.: FDG-PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002, 29:804-808.
28. Kosuda S, Ichihara K, Watanabe M, et al.: Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 2000, 117:346-353.
29. Verboom P, Van Tinteren H, Hoekstra CS, et al.: Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003, 30:1444-1449.
30. Antoch G, Stattaus J, Nemat AT, et al.: Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, in press.
31. Scott WJ, Shepherd J, Gambhir SS: Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998, 66:1876-1883.
32. Cerfolio RJ, Ojha B, Bryant AS, et al.: The role of FDG-PET scan in staging patients with non-small cell carcinoma. Ann Thorac Surg 2003, 76:861-866.
33. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr: Non-small cell lung cancer: FDG-PET for nodal staging in patients with stage I disease. Radiology 2000, 215:886-890.
34. Hoekstra CJ, Stroobants SG, Hockstra OS, et al.: The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003, 39:151-157.
35. Steinert HC, Hauser M, Allemann F, et al.: Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997, 202:441-446.
36. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al.: Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998, 16:2142-2149.
37. Gupta NC, Tamim WJ, Graeber GG, et al.: Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001, 120:521-527.
38. Vesselle H, Pugsley JM, Vallieres E, Wood DE: The impact of fluorodeoxyglucose F 18 positron emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002, 124:511-519.
39. Hsia TC, Shen YY, Yen RF, et al.: Comparing whole-body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 2002, 49:267-271.
40. Weber WA, Petersen V, Schmidt B, et al.: Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657.
41. Mac Manus MP, Hicks RJ, Matthews JP, et al.: Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003, 21:1285-1292.
42. Choi NC, Fischman AJ, Niemierko A, et al.: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG-PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 54:1024-1035.